Exchange: NYSE·Updated 07:59 PM EDT
HIMS logo

HIMSHims & Hers Health Inc

$28.09
$4.65
(14.20%)
Today
Closed $28.09
$0.1036
(0.37%)
After Hours
EarningsAug 10
Mkt Cap$6.5B
Vol28.49M
News
all
press releases
Is Trending Stock Hims & Hers Health, Inc. (HIMS) a Buy Now?
Zacks.com users have recently been watching Hims & Hers Health (HIMS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Zacks
More News
FDA Panel Narrowly Backs Four Peptides Hims & Hers Stock in the Spotlight
Hims & Hers Health is in focus Friday after an FDA advisory panel on Thursday recommended adding four peptides to a federal compounding list.read more...
Benzinga
HIMS Stock Climbs Overnight As FDA Advisory Panel Backs 4 Peptides — ‘Pharma Bro’ Martin Shkreli Goes Short
Leerink sees a $2.2 billion peptide market, with Hims potentially capturing about 20%.
Stocktwits
Nasdaq, S&P 500, Dow Futures Shake Off Iran Jitters As Investors Turn To AI Hyperscaler Earnings: INTC, TSLA, TTD, HIMS In Focus
Markets were primarily focused on earnings from major companies, alongside rising oil prices due to the continued tensions between the U.S. and Iran.
Stocktwits
Why Is Hims & Hers Health Stock Surging on Thursday?
Hims & Hers Health Inc (NYSE: HIMS) stock surges Thursday after an FDA advisory committee votes on adding BPC-157 to the allowed pharmacy compounding list.read more...
Benzinga
Why Is HIMS Stock Rallying 13% Today?
An FDA advisory panel on Thursday recommended adding the peptide BPC-157 to a list that would allow compounding pharmacies to prepare it more freely for patients.
Stocktwits
Hims & Hers Health, Inc. (HIMS) Suffers a Larger Drop Than the General Market: Key Insights
Hims & Hers Health, Inc. (HIMS) closed the most recent trading day at $31.68, moving 3.21% from the previous trading session.
Zacks
HIMS Stock Snaps 3-Day Losing Streak: FDA Adds 8 New Peptide Voters Deemed ‘More Qualified And Less Conflicted’
The new panelists bring expertise in neurology, pain, dermatology, gastroenterology, addiction, cancer pharmacology and patient advocacy.
Stocktwits
Here's How Much You Would Have Made Owning Hims & Hers Health Stock In The Last 5 Years
Hims & Hers Health (NYSE:HIMS) has outperformed the market over the past 5 years by 20.67% on an annualized basis producing an average annual return of 31.83%. Currently, Hims & Hers Health has a marketread more...
Benzinga
HIMS Stock On A 3-Day Slide: CFO Cashes Out $229K In Shares Ahead Of FDA Peptide Meeting
The next major catalyst is the FDA’s July 23-24 advisory committee meeting, where regulators will consider whether seven peptides should be added to the Section 503A Bulks List.
Stocktwits
<
1
2
...
>

Advertisement|Remove ads.